Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07500610 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Observing the Role of Inflammation in Peripheral Artery Disease and Its Impact on Heart and Mobility Health: PANACEA-O.

Study acronym: PANACEA-O
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 30, 2026 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Minor Study First Submitted
This registry aims to collect detailed information about people in Canada who have Peripheral Artery Disease (PAD) and are receiving care in heart clinics while still able to walk and live in the community. Researchers want to better understand what these patients are like at the start of their care and looking at their general health, levels of inflammation in their bodies, and how well they can move and function in daily life. The results of this study will help healthcare providers better understand what PAD looks like in today's Canadian heart clinics. It will also help guide future research studies that focus on inflammation and PAD. The researchers believe that PAD patients can be routinely recruited from these clinics, and that most of these patients will have high levels of inflammation (shown by high blood CRP levels) and poor physical ability when they first join. The findings will show that there is a strong need to regularly check for PAD in heart clinics so that patients can be identified early and offered new treatments in the future and especially treatments that may help reduce inflammation.
Trial Details
NCT Number NCT07500610
Lead Sponsor Cardiology Research UBC
Collaborators: Novo Nordisk A/S
Conditions
(from sponsor)
Peripheral Vascular Disease
Related terms Inflammation, Intermittent Claudication, Peripheral Vascular Diseases
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov